Fresenius SE & Co. (FSNUY) Set to Post Quarterly Earnings on Wednesday

Posted by Nicole Kennedy on Oct 28th, 2026

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) is projected to issue its results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of $0.2156 per share and revenue of $6.51 billion for the quarter.

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). The firm had revenue of $6.91 billion for the quarter, compared to the consensus estimate of $6.65 billion. On average, analysts expect Fresenius SE & Co. to post $1.04 EPS for the current fiscal year and $1.11 EPS for the next fiscal year.

Fresenius SE & Co. Trading Down 0.9%

Shares of OTCMKTS:FSNUY opened at $12.81 on Wednesday. The company has a 50 day moving average of $12.92 and a 200-day moving average of $12.90. Fresenius SE & Co. has a one year low of $10.33 and a one year high of $33.93.

Wall Street Analyst Weigh In

A number of research firms have commented on FSNUY. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating. According to MarketBeat, Fresenius SE & Co. currently has a consensus rating of “Buy”.

Get Our Latest Stock Analysis on Fresenius SE & Co.

Fresenius SE & Co. Company Profile

(Get Free Report)

Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.